This approach, which proved promising in RAS and BRAF wild-type patients candidate for anti-EGFR re-treatment,23,24 showed encouraging signals of activity also in some case series of patients with BRAFV600E-mutated mCRC reexposed to TT after excluding potential drivers of resistance in their circulating tumor DNA,25,26 and may be an appealing approach for future studies. Here, BRAF is linked to neoplasm.